Table 4.

Treatment-emergent adverse events (OT-28).

	n (%), IR/100 PEY
	Roxadustat (N = 215) PEY = 336.2	ESA (N = 204) PEY = 323.7
TEAE	190 (88.4), 56.5	176 (86.3), 54.4
Serious TEAE	125 (58.1), 37.2	116 (56.9), 35.8
TEAE leading to discontinuation of study drug	19 (8.8), 5.7	11 (5.4), 3.4
Grade ≥ 3 TEAE	93 (43.3), 27.7	89 (43.6), 27.5
TEAE leading to death	27 (12.6), 8.0	26 (12.7), 8.0

PEY for each patient = ([last dose date − first dose date] + 1)/365.25. ESA, erythropoiesis-stimulating agent; IR, incidence rate; IR/100 PEY = 100 × number of patients with events/PEY; OT-28, on-treatment period plus 28 days; PEY, patient exposure years; TEAE, treatment-emergent adverse event.